News Esperion and Daiichi Sankyo square up on Nexletol milestone Companies can't see eye to eye on the recently reported data from the CLEAR outcomes study.
News Nexletol shows CLEAR benefit in cardiovascular outcome trial Will a 13% improvement in MACE over placebo be enough to lift lacklustre sales growth?